A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
Condition(s):Metastatic Breast Cancer; Locally Advanced Breast CancerLast Updated:January 24, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Metastatic Breast Cancer; Locally Advanced Breast CancerLast Updated:January 24, 2024Recruiting
Condition(s):Metastatic Breast CancerLast Updated:May 18, 2023Recruiting
Condition(s):Non-Small Cell Lung Cancer (NSCLC)Last Updated:January 17, 2024Recruiting
Condition(s):Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorLast Updated:January 29, 2024Active, not recruiting
Condition(s):Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung CancerLast Updated:March 5, 2024Available
Condition(s):Metastatic Colorectal CancerLast Updated:January 13, 2023Terminated
Condition(s):Metastatic Breast CancerLast Updated:December 15, 2023Completed
Condition(s):Breast CancerLast Updated:June 23, 2023Active, not recruiting
Condition(s):Advanced Solid Tumor; Melanoma; Head and Neck Cancer; Gastric CancerLast Updated:March 13, 2024Recruiting
Condition(s):Nonsquamous Non-small Cell Lung Cancer; EGFR L858R; EGFR Exon 19 DeletionLast Updated:January 11, 2024Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.